Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Chemicals and Drugs (2)
- Food and Drug Law (2)
- Health Law and Policy (2)
- Life Sciences (2)
- Pharmaceutical Preparations (2)
-
- Administrative Law (1)
- Alternative and Complementary Medicine (1)
- Bioethics and Medical Ethics (1)
- Biotechnology (1)
- Clinical Trials (1)
- Commercial Law (1)
- Consumer Protection Law (1)
- Intellectual Property Law (1)
- Marketing Law (1)
- Medical Pharmacology (1)
- Medical Sciences (1)
- Medicinal Chemistry and Pharmaceutics (1)
- Nutrition (1)
- Other Nutrition (1)
- Pharmacoeconomics and Pharmaceutical Economics (1)
- Pharmacology, Toxicology and Environmental Health (1)
- Pharmacy Administration, Policy and Regulation (1)
- Physical Sciences and Mathematics (1)
- Statistics and Probability (1)
Articles 1 - 3 of 3
Full-Text Articles in Law
Dietary Supplement Labeling: Cognitive Biases, Market Manipulation & Consumer Choice, Michael Mccann
Dietary Supplement Labeling: Cognitive Biases, Market Manipulation & Consumer Choice, Michael Mccann
Law Faculty Scholarship
There exists increasing concern that the Dietary Supplements Health and Education Act (DSHEA) has proven ineffective. Much of the concern regards the disparity in legislative treatment between dietary supplements, foods, and pharmaceutical drugs. Namely, while pharmaceutical drugs must undergo years of costly pre-market testing, most supplements, like foods, can immediately enter the market, and only after repeated instances of adverse reactions can the Food and Drug Administration (FDA) remove them. Such a framework appears to belie both consumer expectations and marketing strategies, as supplements tend to be most perceived for their apparent medicinal qualities. This philosophy of waiting for a …
Nudging The Fda, W. Nicholson Price Ii, I. Glenn Cohen
Nudging The Fda, W. Nicholson Price Ii, I. Glenn Cohen
Law Faculty Scholarship
[Excerpt] "The FDA’s regulation of drugs is frequently the subject of policy debate, with arguments falling into two camps. On the one hand, a libertarian view of patients and the health care system holds high the value of consumer choice. Patients should get all the information and the drugs they want; the FDA should do what it can to enforce some basic standards but should otherwise get out of the way. On the other hand, a paternalist view values the FDA’s role as an expert agency standing between patients and a set of potentially dangerous drugs and potentially unscrupulous or …
Making Do In Making Drugs: Innovation Policy And Pharmaceutical Manufacturing, W. Nicholson Price Ii
Making Do In Making Drugs: Innovation Policy And Pharmaceutical Manufacturing, W. Nicholson Price Ii
Law Faculty Scholarship
Despite increasing recalls, contamination events, and shortages, drug companies continue to rely on outdated manufacturing plants and processes. Drug manufacturing’s inefficiency and lack of innovation stand in stark contrast to drug discovery, which is the focus of a calibrated innovation policy that combines patents and FDA regulation. Pharmaceutical manufacturing lags far behind the innovative techniques found in other industries due to high regulatory barriers and ineffective intellectual property incentives. Among other challenges, although manufacturers tend to rely on trade secrecy because of the difficulty in enforcing patents on manufacturing processes, trade secrecy provides limited incentives for innovation. To increase those …